Processa Pharmaceuticals Files Amendment to S-1 Registration Statement

TL;DR

<b>Processa Pharmaceuticals, Inc. has filed an amendment to its S-1 registration statement, indicating ongoing efforts to comply with public offering requirements.</b>

AI Summary

Processa Pharmaceuticals, Inc. (PCSA) filed a Amended IPO Registration (S-1/A) with the SEC on January 22, 2024. Processa Pharmaceuticals, Inc. filed an amendment (S-1/A) to its registration statement on January 22, 2024. The company is incorporated in Delaware and its fiscal year ends on December 31. Its principal executive offices are located at 7380 Coca Cola Drive, Suite 106, Hanover, Maryland 21076. The filing is designated as a non-accelerated filer and a smaller reporting company. The registration statement number is 333-276308.

Why It Matters

For investors and stakeholders tracking Processa Pharmaceuticals, Inc., this filing contains several important signals. This amendment suggests the company is actively working through the process of registering securities for a public offering, which could lead to new capital or liquidity events. As a smaller reporting company and non-accelerated filer, Processa Pharmaceuticals may have different disclosure requirements and market perceptions compared to larger, more established entities.

Risk Assessment

Risk Level: low — Processa Pharmaceuticals, Inc. shows low risk based on this filing. The filing is an amendment to a registration statement, which is a standard procedural step for companies preparing for or undergoing a public offering, and does not inherently indicate significant new risks.

Analyst Insight

Monitor future filings for updates on the registration statement's effectiveness and any subsequent offering details.

Key Numbers

• 333-276308 — Registration Number (S-1 Registration Statement)
• 2024-01-22 — Filing Date (Amendment No. 1 to FORM S-1)
• 2834 — SIC Code (Pharmaceutical Preparations)
• 451539785 — IRS Number (Employer Identification Number)

Key Players & Entities

• Processa Pharmaceuticals, Inc. (company) — Registrant name
• George Ng (person) — Chief Executive Officer
• Foley & Lardner LLP (company) — Legal counsel
• Ellenoff Grossman & Schole LLP (company) — Legal counsel
• Delaware (jurisdiction) — State of incorporation
• Maryland (jurisdiction) — Business address state

Forward-Looking Statements

• Processa Pharmaceuticals will complete its public offering of securities. (Processa Pharmaceuticals, Inc.) — medium confidence, target: Q1 2024

FAQ

Industry Context

Processa Pharmaceuticals operates within the pharmaceutical preparations industry, focusing on the development and commercialization of pharmaceutical products.

Regulatory Implications

The filing is made under the Securities Act of 1933, which governs the registration of securities offered to the public in the United States.

What Investors Should Do

1. Review the full S-1/A filing for details on the securities being registered and the intended use of proceeds.
2. Track subsequent SEC filings for updates on the registration statement's effectiveness and any potential public offering.
3. Research Processa Pharmaceuticals' business strategy and pipeline to assess its long-term prospects.

Year-Over-Year Comparison

This is an amendment to a previously filed registration statement, indicating ongoing procedural steps rather than a new filing event.

Key Financial Figures

• $4.00 — sumed combined public offering price of $4.00 per share of common stock and accompany
• $0.125 — hare under Nasdaq rule 5635(d) plus (b) $0.125 per whole share of common stock underly
• $0.0001 — of common stock at an exercise price of $0.0001 per share of common stock. The public o
• $112,500 — ees and expenses in the amount of up to $112,500, and for its clearing expenses in the a
• $15,950 — its clearing expenses in the amount of $15,950. In addition, we have agreed to issue t
• $5.00 — mpany), at an assumed exercise price of $5.00 per share, which represents 125% of the

Filing Documents

• forms-1a.htm (S-1/A) — 736KB
• ex3-1_6.htm (EX-3.1_6) — 16KB
• ex4-2.htm (EX-4.2) — 125KB
• ex4-3.htm (EX-4.3) — 134KB
• ex4-4.htm (EX-4.4) — 129KB
• ex5-1.htm (EX-5.1) — 23KB
• ex10-14.htm (EX-10.14) — 262KB
• ex23-1.htm (EX-23.1) — 3KB
• forms-1a_001.jpg (GRAPHIC) — 7KB
• forms-1a_002.jpg (GRAPHIC) — 120KB
• forms-1a_003.jpg (GRAPHIC) — 7KB
• ex5-1_001.jpg (GRAPHIC) — 4KB
• 0001493152-24-003101.txt (&nbsp;) — 1621KB

Executive Compensation

Executive Compensation 21 Beneficial Ownership 29 Description of Capital Stock 31 Description of Securities We Are Offering 35 Material U.S. Federal Income Tax Consequences 39 Plan of Distribution 45 Legal Matters 47 Experts 47 Incorporation of Certain Information by Reference 47 Where You Can Find More Information 48 i ABOUT THIS PROSPECTUS You should rely only on the information we have provided or incorporated by reference into this prospectus, any applicable prospectus supplement and any related free writing prospectus. We incorporate by reference important information into this prospectus. You may obtain the information incorporated by reference without charge by following the instructions under &ldquo;Where You Can Find More Information.&rdquo; You should carefully read this prospectus as well as additional information described under &ldquo;Incorporation of Certain Information By Reference,&rdquo; before deciding to invest in our securities. We have not, and the placement agent and its affiliates have not, authorized anyone to provide you with any information or to make any representation not contained or incorporated by reference in this prospectus or any related free writing prospectus. We do not, and the placement agent and its affiliates do not, take any responsibility for, and can provide no assurance as to the reliability of, any information that others may provide to you. This prospectus is not an offer to sell or an offer to buy securities in any jurisdiction where offers and sales are not permitted. The information in this prospectus is accurate only as of its date, regardless of the time of delivery of this prospectus or any sale of securities. You should also read and consider the information in the documents to which we have referred you under the caption &ldquo;Where You Can Find More Information&rdquo; in the prospectus. To the extent there is a conflict between the information contained in this prospectus,

View Full Filing

View this S-1/A filing on SEC EDGAR